News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Asembia 2025 |
Sales Effectiveness|
Latest Executive Roundtables
Advertisement

Pouria Sanae

Advertisement
Pouria Sanae

Co-founder and CEO, ixlayer

Articles by Pouria Sanae

Engaging Patients: Why Pharma’s Direct-to-Patient Approach Should Be Applauded

ByPouria Sanae
January 16th 2025

Physicians remain central even as DTP programs are implemented.

Advertisement

Latest Updated Articles

  • Engaging Patients: Why Pharma’s Direct-to-Patient Approach Should Be Applauded
    Engaging Patients: Why Pharma’s Direct-to-Patient Approach Should Be Applauded

    Published: January 16th 2025 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

Ypsomed Announces New U.S.-Based Manufacturing Site in North Carolina

2

AstraZeneca to Announce Deal with Trump Administration: Report

3

Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics

4

Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape

5

Navigating Pharmacy Models and Regulatory Pitfalls When Launching Direct-To-Consumer Programs

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us